Overall, these data show that inhibition of SLC4A4 in combination with ICB strongly reduces tumor growth and cancer aggressiveness, paving the way toward a possible therapeutic strategy to overcome PDAC resistance to immunotherapy. Here, SLC4A4 is linked to cancer.